Aprea Therapeutics
12 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of APR-1051 in Patients With Advanced Solid Tumors (NCT06260514) | Aprea Therapeutics | 2024-06-13 |
| Study Of ATRN-119 In Patients With Advanced Solid Tumors (NCT04905914) | Aprea Therapeutics | 2023-01-09 |
| APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (NCT04638309) | Aprea Therapeutics | 2021-09-20 |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (NCT04419389) | Aprea Therapeutics | 2021-03-02 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies (NCT04383938) | Aprea Therapeutics | 2020-06-25 |
| APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies (NCT04214860) | Aprea Therapeutics | 2019-12-13 |
| A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma (NCT03391050) | Aprea Therapeutics | 2018-01-18 |
Track Aprea Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.